Therapeutics Uses of Psychedelics in Patients With Psychiatric Disorders a Systematic Review
DOI:
https://doi.org/10.56570/jimgs.v1i1.155Keywords:
Psychedelic/ Psychotropic drugs/ Hallucinogen, Serotonin receptors, LSD, mescaline, ayahuasca, Therapeutic uses, Psychiatric Diseases/Mental health, PsychotherapyAbstract
The impact of psychedelic treatment on patients suffering from psychiatric diseases like depression, anxiety, post-traumatic psychiatric disorder (PTSD), and existential distress related to cancer has become very intriguing to psychiatrists in the modern era. Serotonergic psychedelics include Lysergic acid diethylamide (LSD), psilocybin, mescaline, ayahuasca, and methylene-deoxy methamphetamine (MDMA) which act agonistically on 5-hydroxytryptamine type 2-A (5-HT2A) receptors. Psychedelics produce a wide range of effects, based on varying sites of 5-HT2a receptors, including changes in consciousness, perception, mood, and behaviour. Psychedelics can lead to both good and bad trips depending on the dose and environment in which it is taken. We used systematic approach by strictly following Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) 2020 guidelines. Data is extracted from pub med using mesh strategy, and from google scholar and science direct by using keywords. 10 review articles are selected by using quality appraisal tools. The purpose of this paper is to highlight the mechanism of action and role of psychedelics in patients with mental health disorders. In this review, we discussed the effective models of neurodynamical changes produced by psychedelics, and we also show that these substances can be used as a potential treatment option for psychiatric patients. Psychedelics have shown effective improvement in psychiatric diseases in many pilot studies and randomized controlled trials. There is still a debate going on about which models best suggest their role in the field of psychiatry.References
Alcohol and Drug Foundation. Psychedelics - Alcohol and Drug Foundation [Internet]. Adf.org.au. 2021. Available from: https://adf.org.au/drug-facts/psychedelics/
Alcohol and Drug Foundation. Psychedelics - Alcohol and Drug Foundation [Internet]. Adf.org.au. 2021.
Belouin SJ, Henningfield JE. Psychedelics: Where we are now, why we got here, what we must do. Neuropharmacology [Internet]. 2018 Nov;142:7–19. Available from: https://pubmed.ncbi.nlm.nih.gov/29476779/
Wikipedia Contributors. History of lysergic acid diethylamide [Internet]. Wikipedia. Wikimedia Foundation; 2019. Available from: https://en.wikipedia.org/wiki/History_of_lysergic_acid_diethylamide
Tanne, Jannice. Humphry Osmond. BMJ [Internet]. 2004 Mar 18 [cited 2021 Feb 28];328(7441):713. Available from: https://doi.org/10.1136/bmj.328.7441.713
Hammel RL, Gulliver BJ, Sukich SN, Abraham SP. The Role of Psychedelics in Managing Anxiety, Depression, and Flashbacks of Individuals with Post-Traumatic Stress Disorder. International Journal of Science and Research Methodology [Internet]. 2022 Jan 31 [cited 2022 Mar 28];20(3):143–61. Available from: https://ijsrm.humanjournals.com/wp-content/uploads/2022/02/10.Reace-L.-Hammel-Berry-J.-Gulliver-Shelby-N.-Sukich-Samuel-P.-Abraham.pdf
Ross S, Agrawal M, Griffiths RR, Grob C, Berger A, Henningfield JE. Psychedelic-assisted psychotherapy to treat psychiatric and existential distress in life-threatening medical illnesses and palliative care. Neuropharmacology [Internet]. 2022 Sep;216:109174. Available from: https://doi.org/10.1016/j.neuropharm.2022.10917
Nichols DE. Psychedelics. Pharmacological Reviews [Internet]. 2016 Feb 3;68(2):264–355. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4813425/
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of Clinical Epidemiology [Internet]. 2009 Oct;62(10):e1–34. Available from: https://www.sciencedirect.com/science/article/pii/S08 95435609001802
PRISMA. PRISMA flow diagram [Internet]. www.prisma-statement.org. 2020. Available from: http://www.prisma-statement.org/PRISMAStatement/FlowDiagram
Baethge C, Goldbeck-Wood S, Mertens S. SANRA—a scale for the quality assessment of narrative review articles. Research Integrity and Peer Review [Internet]. 2019 Mar 26;4(1). Available from: https://researchintegrityjournal.biomedcentral.com/art icles/10.1186/s41073-019-0064-8
Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ [Internet]. 2017 Sep 21;358(8122):j4008. Available from: https://www.bmj.com/content/358/bmj.j4008
Crane M. Drug Classifications: Scheduling of Narcotics and Prescription Drugs [Internet]. American Addiction Centers. 2018. Available from: https://americanaddictioncenters.org/prescription-drugs/classifications
Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nature Reviews Neuroscience [Internet]. 2020 Sep 14;21(11):611–24. Available from: https://www.nature.com/articles/s41583-020-0367-2
Nutt D, Spriggs M, Erritzoe D. Psychedelics therapeutics: What we know, what we think, and what we need to research. Neuropharmacology [Internet]. 2022 Sep [cited 2022 Oct 1];109257. Available from: https://doi.org/10.1016/j.neuropharm.2022.109257
Kent J. Neurotransmitters & Neuromodulators: The Psychedelic Connection : James Kent [Internet]. www.tripzine.com. Available from: http://www.tripzine.com/listing.php?smlid=362
Aqil M, Roseman L. More than meets the eye: The role of sensory dimensions in psychedelic brain dynamics, experience, and therapeutics. Neuropharmacology [Internet]. 2023 Feb [cited 2022 Nov 26];223:109300. Available from: https://doi.org/10.1016/j.neuropharm.2022.109300
Rucker JJH, Iliff J, Nutt DJ. Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology [Internet]. 2018 Nov;142:200–18. Available from: https://www.sciencedirect.com/science/article/pii/S00 2839081730638X
Javidi H, Yadollahie M. Post-traumatic Stress Disorder. The International Journal of Occupational and Environmental Medicine [Internet]. 2012 Jan 1;3(1):2–9. Available from: https://pubmed.ncbi.nlm.nih.gov/23022845/
Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology [Internet]. 2016 Nov 30;30(12):1181–97. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367557/
Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, et al. Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer. Archives of General Psychiatry [Internet]. 2011 Jan 3;68(1):71. Available from: https://doi.org/10.1001/archgenpsychiatry.2010.116
Ameli R, Sinaii N, Luna MJ, Cheringal J, Gril B, Berger A. The National Institutes of Health measure of Healing Experience of All Life Stressors (NIH-HEALS): Factor analysis and validation. ten Klooster PM, editor. PLOS ONE [Internet]. 2018 Dec 12;13(12):e0207820. Available from: https://doi.org/10.1371/journal.pone.0207820
Ross S. Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. International Review of Psychiatry. 2018 Jul 4;30(4):317–30.
Ayahuasca [Internet]. Multidisciplinary Association for Psychedelic Studies - MAPS. Available from: https://maps.org/ayahuasca/
Chao YS, Horton J. Psychedelic-Assisted Psychotherapy for Post-Traumatic Stress Disorder, Anxiety Disorders, Mood Disorders, or Substance Use Disorders [Internet]. PubMed. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021. Available from: https://pubmed.ncbi.nlm.nih.gov/36170470/
Nichols DE, Walter H. The History of Psychedelics in Psychiatry. Pharmacopsychiatry [Internet]. 2020 Dec 7;54(4). Available from: https://doi.org/10.1055/a-1310-3990
Turton S, Nutt DJ, Carhart-Harris RL. A Qualitative Report on the Subjective Experience of Intravenous Psilocybin Administered in an fMRI Environment. Current Drug Abuse Reviews [Internet]. 2015 Jan 27 [cited 2019 Oct 29];7(2):117–27. Available from: https://doi.org/10.2174/1874473708666150107120930
Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, et al. Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects. Biological Psychiatry [Internet]. 2015 Oct;78(8):544–53. Available from: https://doi.org/10.1016/j.biopsych.2014.11.015
Lebedev AV, Lövdén M, Rosenthal G, Feilding A, Nutt DJ, Carhart-Harris RL. Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin. Human Brain Mapping. 2015 May 22;36(8):3137–53. doi: 10.1002/hbm.22833
Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychological Medicine. 2018 Jun 15;49(4):655–63. doi:10.1017/S0033291718001356
Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific Reports [Internet]. 2017 Oct 13;7(1). DOI: 10.1038/s41598-017-13282-7
Johnson MW, Hendricks PS, Barrett FS, Griffiths RR. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology & Therapeutics. 2019 May;197:83–102. DOI: 10.1016/j.pharmthera.2018.11.010
Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, et al. Psilocybin with Psychological Support for treatment-resistant depression: an open-label Feasibility Study. The Lancet Psychiatry [Internet]. 2016 Jul;3(7):619–27. DOI: 10.1016/S2215-0366(16)30065-7
Carhart-Harris RL, Friston KJ. REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics. Barker EL, editor. Pharmacological Reviews. 2019 Jun 20;71(3):316–44. doi: 10.1124/pr.118.017160
